Vas Narasimhan, CEO of Novartis, was appointed to Anthropic's Board of Directors by the Long-Term Benefit Trust on April 14, 2026.
This marks the first healthcare executive on Anthropic's board, emphasizing AI's role in drug discovery and life sciences.14
Narasimhan, a physician-scientist with degrees from University of Chicago and Harvard, brings expertise in regulations and ethics.1
The appointment gives Trust-appointed directors a majority on the board, including Narasimhan alongside Dario Amodei, Reed Hastings, and others.46
Anthropic is strengthening biopharma ties, with partnerships like Sanofi, Novo Nordisk, and AbbVie.3
No search results provided details on Metsera alum joining Structure as COO.
Sources:
1. https://www.ndtvprofit.com/business/who-is-vas-narasimhan-novartis-ceo-appointed-to-anthropics-board-11358919
3. https://www.biospace.com/business/novartis-ceo-joins-anthropic-board-embedding-ai-in-the-heart-of-biopharma
4. https://www.anthropic.com/news/narasimhan-board
6. https://www.rdworldonline.com/anthropics-oversight-trust-just-hit-majority-control-the-tipping-point-was-adding-novartis-ceo-vas-narasimhan-to-its-board/